5PSQ-071 Efficacy and safety evaluation of trifluridine/tiparacil for metastatic colon cancer (mcrc)

BACKGROUND: Trifluridine/tiparacile is the second oral treatment approved for patients with mCRC who have received fluoropyrimidine, oxaliplin- and irinotecan-based chemotherapy, an anti-VEGF biologic therapy and, if RAS wild-type, an anti-EGFR. PURPOSE: To evaluate the efficacy and safety of patien...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Hosp Pharm
Main Authors: Herrera, S Guijarro, Domínguez, S Cano, Fumero, R García, Rodríguez-Hermida, F Artime, Soto, C Valencia, Zúñiga, L Gutiérrez, Morales, A Jiménez, García, C Collado
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2018
Assuntos:
Section 5: Patient safety and quality assurance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535737/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.425
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados